key: cord-0808983-73bl1jbx authors: Kochanek, Matthias; Borrega, Jorge Garcia; Beckmann, Laura; Gathof, Birgit S; Di Cristanziano, Veronica; Hagmann, Henning title: Plasma exchange with COVID-19 convalescent plasma in a patient with severe ANCA-associated vasculitis and COVID-19 pneumonia after rituximab therapy date: 2021-05-27 journal: Clin Kidney J DOI: 10.1093/ckj/sfab095 sha: 51135614d0c3b25fa80e94dd93bc40decbdd62f0 doc_id: 808983 cord_uid: 73bl1jbx The combination of COVID-19 pneumonia and pulmonary-renal syndrome due to ANCA‐associated vasculitis (AAV) pose diagnostic uncertainty and a therapeutic dilemma. According to current limited knowledge of COVID-19, the application of commonly used drugs in AAV, cyclophosphamide and rituximab, must be weighed carefully in active COVID-19 infection. We report a case of a 52-year-old male patient with concurrent severe COVID-19 pneumonia and acute relapse of pulmonary-renal syndrome due to AAV after recent rituximab maintenance dose. The patient presented with severe hypoxemia, complete B-cell depletion and SARS-CoV-2 viremia. He was successfully treated with therapeutic plasma exchange employing COVID-19 convalescent plasma. In the absence of infection or known SARS-CoV-2 exposure, American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) recommend continuation of ongoing immunosuppressive therapy in patients with systemic rheumatologic diseases 1 . Although scientific evidence is sparse, an exception to this recommendation might be treatment with B-cell directed therapy, e.g. Rituximab (RTX) 2 . RTX specifically depletes CD20-positive B lymphocytes, hampering protective antibody-mediated immunity following infection and vaccination. Case reports and observational studies indicate staggering poor prognosis of COVID-19 in patients treated with RTX for rheumatologic diseases 3 . Early on during the pandemic, experts speculated that patients with RTX-induced hypogammaglobulinemia and severe COVID-19 could profit from treatment with COVID-19 convalescent plasma (CCP) 4 . Herein we report a case of a 52-year-old male patient with severe COVID-19 pneumonia and acute relapse of AAV 18 days after the first maintenance dose of rituximab according to MAINRITSAN protocol. The patient was successfully treated with therapeutic plasma exchange (TPE) substituting CCP. On admission to our ICU, the patient had a 2-week history of hemoptysis, fever and shortness of breath. A chest CT-scan showed left mid-zone consolidation, resembling both patterns found in COVID peak stage 3 and pulmonary-renal syndrome associated with AAV. COVID-19 nasopharyngeal swabs tested SARS-CoV-2 RNA positive. In addition, SARS-CoV-2 RNAemia was detected, indicating a higher risk for severe COVID-19 5 . Routine bloods tests were performed. Pertinent values are outlined in Table 1 . qSOFA on admission was 0, APACHE and SOFA score 17 and 6, respectively. High-Flow Nasal Oxygen (HFNO) was initiated immediately due to severe hypoxemia. Elevated MPO-ANCA levels of 533 RE/ml confirmed the relapse of AAV. Immunophenotyping of lymphocytes showed complete B-cell depletion. Treatment with high-dose glucocorticoids (250mg prednisolone qd) was initiated. TPE was performed five times on consecutive days, processing 4 liters plasma during each treatment and substituting CCP. According to previous studies 6 , two units of high titer CCP (quality A, "high titer" containing SARS Cov-2 IgG > 3 (Euroimmun ELISA) and/or neutralizing activity > 250) were transfused at the end of each TPE. The other plasma used in TPE were low titer CCP (quality B, SARS-CoV-2 IgG and neutralizing activity > 50, quality C: SARS-CoV 2 IgA/IgG Antibodies with or without detection of neutralizing antibodies). CCP was manufactured with authorization of the local government and according to recommendations of the German end EU authorities (EU-Guidance 7 ). In total, 79 CCP were transfused (18 quality A, 14 quality B and 47 quality C). We were able to generate a sufficiently high titer of anti-SARS-CoV-2 antibody to control COVID-19 pneumonia early after admission (Fig. 1 ). In addition, we achieved sufficient clearing of ANCA and pro-inflammatory cytokines (Suppl. Fig. 1A) . Defervescence occurred two days after ICU admission. On day 6, the patient received 1000 mg of cyclophosphamide and was weaned of the HFNO. The patient was transferred to the regular ward on day 9 and discharged on day 16. The patient received 120mg prednisolone qd on discharge with continued tapering. SARS-CoV-2 IgG titers increased to day 14 and remained high for one month follow-up, indicating active humoral immune response even under persisting B-cell depletion. There is still uncertainty which ongoing immunosuppressive regimens pose an additional risk in case of SARS-CoV-2 infection. While some biologicals and small molecules showed no harmful or even beneficial effects (e.g. tocilizumab, baricitinib) in COVID-19, RTX was associated with poor outcomes 3, 8 . For patients with COVID-19 under RTX, at present no therapeutic strategy is defined. Our patient not only presented with severe COVID-19 pneumonia after recent application of RTX. In addition, he suffered from an acute relapse of AAV necessitating immediate therapeutic intervention. In AAV glucocorticoid (GC) pulse plus immunosuppressive therapy comprising rituximab (RTX) or cyclophosphamide (CYC) or a combination of both are effective in reducing mortality and end-stage renal disease 9 . The use of TPE had been supported by former trials for rapid control of disease activity. In latest large randomized trials, however, the additional benefits of TPE were limited 10 . Hence, TPE is no longer inherent part of induction therapy in AAV. In the present case of acute AAV, severe COVID-19 pneumonia and depletion of B-cells after RTX, which implies hampered humoral immune response to SARS-CoV-2, we decided for TPE with CCP as the substitute. The patient condition rapidly improved during the five days of TPE. Strikingly, even in the absence of detectable B-cells the patient was able to generate SARS-CoV-2 specific IgG 2-3 weeks after infection. We show that TPE with CCP was safe and feasible in COVID-19 pneumonia in an immunocompromised patient and most likely improved the clinical outcome. We declare no competing interests. The patient provided informed consent for publication of this case report. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 100x237mm (300 x 300 DPI) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 CKJ-00320-2021-fig1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial An EU programme of COVID-19 convalescent plasma collection and transfusion Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study Longterm follow-up of a combined rituximab and cyclophosphamide regimen in renal antineutrophil cytoplasm antibody-associated vasculitis Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis We thank B. Böll, D.A. Eichenauer, A. Shimabukuro-Vornhagen, and J. Neuhann for valuable discussion of the case and manuscript. None declared.